ADK.V - DIAGNOS Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.0400
0.0000 (0.00%)
At close: 3:43PM EDT
Stock chart is not supported by your current browser
Previous Close0.0400
Open0.0350
Bid0.0350 x 0
Ask0.0400 x 0
Day's Range0.0350 - 0.0400
52 Week Range0.0300 - 0.1000
Volume270,000
Avg. Volume917,290
Market Cap8.517M
Beta (3Y Monthly)3.18
PE Ratio (TTM)N/A
EPS (TTM)-0.0230
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire3 days ago

    DIAGNOS Will Supply Its Artificial Intelligence Technology to the First Hypertensive Retina Screening Clinic in Saudi Arabia.

    DIAGNOS Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK), (DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today it will supply its Artificial Intelligence technology to the first Hypertensive Retina Screening Clinic in Saudi Arabia with Kanhoor Medical Inc. (“Kanhoor”). “We are delighted to open our first screening clinic for HBP in collaboration with DIAGNOS”, said the President of Kanhoor, Mr. Rashid AlMugait.

  • CNW Group9 days ago

    IIROC Trading Resumption - ADK

    IIROC Trading Resumption - ADK

  • GlobeNewswire9 days ago

    DIAGNOS Announces Approval of Corporate Reorganization

    BROSSARD, Quebec, April 10, 2019 -- DIAGNOS Inc. (“DIAGNOS”, “the Corporation” or “we””) (TSX Venture: ADK), (OTCQB: DGNOF), a leader in early detection of critical health.

  • CNW Group9 days ago

    IIROC Trading Halt - ADK

    IIROC Trading Halt - ADK

  • GlobeNewswire17 days ago

    DIAGNOS Announces New Contract with Government in Bangladesh Through its Partner Eyes for All

    DIAGNOS Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK), (DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today the opening of the first eye screening diabetic clinic with a world leading global health research institute in Dhaka, Bangladesh. The International Diabetes Federation (“IDF”) estimates that by 2030, Bangladesh would emerge as one of the countries with the largest number of people with type 2 diabetes.

  • GlobeNewswire23 days ago

    DIAGNOS Announces an Update to the News Release Issued Earlier Today

    DIAGNOS Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK), (DGNOF), a leader in early detection of critical health issues through the use of its proprietary FLAIRE platform based on Artificial Intelligence (AI), announces an update to provide more details with regards to the news release issued earlier today for the signing of a memorandum of understanding between one hospital in the US (the “Partner”) and DIAGNOS. DIAGNOS expects to sign a definitive agreement with Partner within 45 days from the date of this news release.

  • GlobeNewswire23 days ago

    DIAGNOS Announces Memorandum of Understanding with one of the 5 largest hospitals in the US for the final development of its CARDIO application

    DIAGNOS Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK), (DGNOF), a leader in early detection of critical health issues through the use of its proprietary FLAIRE platform based on Artificial Intelligence (AI), announces today the signing of a memorandum of understanding to establish a framework between one hospital in the US and DIAGNOS. Under the terms of a mutual non-disclosure agreement, the name of the hospital can’t be disclosed.  The hospital is engaged and specializes in the medical field of stroke and related cardiological issues.  The hospital has one of the largest databases in the world for stroke related patients. DIAGNOS will utilize this database to finalize the development and validation for CARDIO.

  • GlobeNewswirelast month

    DIAGNOS Announces New Agreement in the United Arab Emirates with one of the Largest Pharmaceutical Companies in the World

    DIAGNOS Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK), (DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today the signing of a significant renewal contract in the United Arab Emirates consisting of a turnkey one-year screening contract for 2 CARA platform services. During the period covered by the agreement, DIAGNOS estimates that an additional 5,000 patients will be screened in UAE using its CARA platform.

  • Have Insiders Been Buying DIAGNOS Inc. (CVE:ADK) Shares?
    Simply Wall St.last month

    Have Insiders Been Buying DIAGNOS Inc. (CVE:ADK) Shares?

    It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also plenty of examples of share prices declining precipitously after insidersRead More...

  • GlobeNewswirelast month

    DIAGNOS Announces Corporate Reorganization

    DIAGNOS Inc. (“DIAGNOS”, “the Corporation” or “we””) (TSX Venture: ADK), (DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces that it has taken steps to reorganize its debt and capital structure to allow it to efficiently allocate its resources and pursue the growth of the business. As such, Diagnos has put in place a special reorganization team to cover all strategic, legal, organizational and financial aspects of the proposed reorganization.

  • GlobeNewswire3 months ago

    DIAGNOS Welcomes Dr. Jean-Francois Yale to the Board of Directors

    Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK) (DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), is pleased to announce the appointment of Dr. Jean-Francois Yale to its board of directors. Dr. Yale is an endocrinologist, currently professor of medicine at the McGill University Department of Medicine. Dr. Yale chaired the Clinical and Scientific Section of the Canadian Diabetes Association from 1992-1994 as well as the Expert Committee that published the 2001 Clinical Practice Guidelines for the Prevention and Management of Diabetes.

  • GlobeNewswire3 months ago

    DIAGNOS Announces an Extension to the Diabetic Retinopathy Screening Services Assisted by Artificial Intelligence (AI) at the CHUM

    DIAGNOS Inc. (“DIAGNOS” or the “Company”) (TSX Venture Exchange: ADK) (DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today, further to our initial news release dated June 5th, 2018, the extension through May 2019 of the technological showcase for the automated detection of Diabetic Retinopathy at the Centre Hospitalier de l’Université de Montréal (CHUM). DIAGNOS will continue screening for diabetic retinopathy at the CHUM until the end of May 2019.

  • GlobeNewswire4 months ago

    DIAGNOS Announces Closing of Private Placement

    BROSSARD, Quebec, Dec. 12, 2018 -- DIAGNOS Inc. (“DIAGNOS”, the “Corporation” or the “Issuer”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health.

  • GlobeNewswire4 months ago

    DIAGNOS is announcing a collaboration with ÉTS on Automated detection and grading of Diabetic Retinopathy using Deep Convolutional Neural Networks, (CNN) a new generation of Deep Learning Technique  

    BROSSARD, Quebec, Dec. 04, 2018 -- Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture:ADK), (OTCQB: DGNOF), a leader in early detection of critical health issues.

  • GlobeNewswire5 months ago

    DIAGNOS Announces Final Closing of Private Placement

    BROSSARD, Quebec, Nov. 21, 2018 -- DIAGNOS Inc. (“DIAGNOS”, the “Corporation” or the “Issuer”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health.

  • GlobeNewswire5 months ago

    DIAGNOS Enters into a Shares for Debt Transaction

    DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence, announces today it has entered into a shares for debt arrangement in which the Corporation is issuing 900,000 common shares (each a “Share”), at a deemed price of $0.05 per Share, in settlement for interests payable in the amount of $45,000 on outstanding unsecured convertible notes (each a “Note”) totaling $900,000. Satisfying this outstanding indebtedness with shares was undertaken in order to preserve the Corporation’s cash for operational purposes. Two Note holders eligible to receive common shares as part of the shares for debt transaction are considered “related parties” of the Corporation within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”).

  • GlobeNewswire5 months ago

    DIAGNOS Announces Today the Addition of a Strategic Partner in the Country of Mexico

    DIAGNOS Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture:ADK), (DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces today the addition of a strategic partner in the country of Mexico.  This agreement will enlarge the footprint coverage of DIAGNOS’ offering for monitoring diabetic patients through our first partner in that country. “Today we all (my family and I), accepted unanimously to go with DIAGNOS in this adventure, we truly believe both of us will do great and together will achieve important objectives”, declares Quim. “Mr. Andre Larente visited me in Monterrey city, my hometown at my brand new office, we clicked right away because we both are men of one vision: to provide the best diagnostic technology to prevent and leverage the health quality of people.” “I also met Mr. Georges Herbert Chairman of DIAGNOS Inc, during his visit to Mexico City.

  • GlobeNewswire5 months ago

    DIAGNOS Announces Private Placement of Common Stocks and Stock Warrants

    DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence, announces a private placement (“Private Placement”) of up to 16,160,000 units (each a “Unit”) issued at $0.05 per Unit for gross proceeds of up to $808,000. It is expected that one participant in the Private Placement will become a “related party” of DIAGNOS within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The participant will exercise, as a result of the Private Placement, control up to 19.10% of the common shares of DIAGNOS.

  • GlobeNewswire6 months ago

    DIAGNOS Announces Closing of Private Placement of Common Stocks and Stock Warrants

    BROSSARD, Québec, Nov. 01, 2018 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence, announces the closing of a private placement (“Private Placement”) of 10,000,000 units (each a “Unit”) issued at $0.05 per Unit for gross proceeds of $500,000. The Private Placement was initially announced on October 24th, 2018 for gross proceeds of up to $400,000.